Jaguar Health vs Sunshine Biopharma
Sunshine Biopharma is the larger business, with $36.3m of revenue in fiscal 2025 against $11.5m for Jaguar Health (3.2 times as much). Sunshine Biopharma grew faster (4.1% against -1.5%). Sunshine Biopharma kept more of each dollar of sales as profit: a net margin of -16.5% against -465.4%.
| Latest fiscal year | Jaguar HealthJAGX, 2025 | Sunshine BiopharmaSBFM, 2025 |
|---|---|---|
| Revenue | $11.5m | $36.3m |
| Revenue growth | -1.5% | 4.1% |
| Net income | −$53.6m | −$6.0m |
| Operating margin | -398.8% | -17.2% |
| Net margin | -465.4% | -16.5% |
| Return on equity | — | -25.7% |
| Free cash flow | −$23.7m | −$5.5m |
| Cash | $968,000 | $9.1m |
| Total debt | $42.5m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | — | 50 |
| Market value | $439,515 | $6.5m |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 15 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |